Skip Navigation

British Journal of Anaesthesia 2005 95(3):281-284; doi:10.1093/bja/aei204
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jones, S. F.
Right arrow Articles by Power, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, S. F.
Right arrow Articles by Power, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Board of Management and Trustees of the British Journal of Anaesthesia 2005. All rights reserved. For Permissions, please e-mail: journal.permissions@oupjournals.org

EDITORIAL

Editorial I: Postoperative NSAIDs and COX-2 inhibitors: cardiovascular risks and benefits

S. F. Jones

Waikato Hospital, Hamilton, New Zealand

I. Power*

School of Clinical Sciences and Community Health, The University of Edinburgh Royal Infirmary, Little France, Edinburgh EH16 4SA, UK

* Corresponding author. E-mail: Ian.Power@ed.ac.uk

The first 150 words of the full text of this article appear below.

"I would have everie man write what he knowes and no more."—Montaigne

The identification of a second isoenzyme of cyclo-oxygenase (COX-2), induced at the site of injury or inflammation, raised the prospect of analgesia without some of the adverse effects associated with the traditional non-steroidal anti-inflammatory drugs (NSAIDs). Preferential COX-2 inhibition was identified in some existing drugs, such as meloxicam, and a new family of drugs, the coxibs, was developed with still greater selectivity: celecoxib, rofecoxib and lumaricoxib exhibit COX-1:COX-2 inhibitory ratios of 1:30, 1:276 and 1:433, respectively. The selective COX-2 inhibitors were developed to exploit a minor conformational difference between the cyclo-oxygenase isoforms, binding to the same sites but able to be accommodated only by the COX-2 enzyme because of its distinguishing side pocket.

Theoretical concerns about a possible increase in the risk of adverse cardiovascular events appeared to be borne out when a 5-fold increase in the incidence . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Br J AnaesthHome page
G. Riest, J. Peters, M. Weiss, S. Dreyer, P. D. Klassen, B. Stegen, A. Bello, and M. Eikermann
Preventive effects of perioperative parecoxib on post-discectomy pain
Br. J. Anaesth., February 1, 2008; 100(2): 256 - 262.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
B. Carvalho, L. Chu, A. Fuller, S. E. Cohen, and E. T. Riley
Valdecoxib for postoperative pain management after cesarean delivery: a randomized, double-blind, placebo-controlled study.
Anesth. Analg., September 1, 2006; 103(3): 664 - 670.
[Abstract] [Full Text] [PDF]